Nagy G, Roodenrijs NM, Welsing PM, Kedves M, Hamar A, van der Goes MC, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021;80(1):31–5.

PubMed  Google Scholar 

Takanashi S, Kaneko Y, Takeuchi T. Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice. Rheumatology. 2021;60(11):5247–56.

CAS  PubMed  Google Scholar 

Novella-Navarro M, Ruiz-Esquide V, Torres-Ortiz G, Chacur CA, Tornero C, Fernández-Fernández E et al. A paradigm of difficult-to-treat rheumatoid arthritis: subtypes and early identification. Clin Exp Rheumatol [Internet]. 2022 May 19 [cited 2024 Jul 21]; Available from: https://www.clinexprheumatol.org/abstract.asp?a=18765

Watanabe R, Hashimoto M, Murata K, Murakami K, Tanaka M, Ohmura K, et al. Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: the KURAMA cohort. Immunol Med. 2022;45(1):35–44.

CAS  PubMed  Google Scholar 

Buch MH, Eyre S, McGonagle D. Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nat Rev Rheumatol. 2021;17(1):17–33.

PubMed  Google Scholar 

Fletcher A, Lassere M, March L, Hill C, Barrett C, Carroll G, et al. Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia. Rheumatol Oxf Engl. 2022;61(10):3939–51.

CAS  Google Scholar 

Matsson A, Solomon DH, Crabtree MM, Harrison RW, Litman HJ, Johansson FD. Patterns in the sequential treatment of patients with rheumatoid arthritis starting a biologic or targeted synthetic Disease-Modifying antirheumatic drug: 10‐Year experience from a US‐Based registry. ACR Open Rheumatol. 2023;6(1):5–13.

PubMed  PubMed Central  Google Scholar 

McDermott GC, DiIorio M, Kawano Y, Jeffway M, MacVicar M, Dahal K, et al. Reasons for multiple biologic and targeted synthetic DMARD switching and characteristics of treatment refractory rheumatoid arthritis. Semin Arthritis Rheum. 2024;66:152421.

CAS  PubMed  PubMed Central  Google Scholar 

Novella-Navarro M, Benavent D, Ruiz-Esquide V, Tornero C, Díaz-Almirón M, Chacur CA, et al. Predictive model to identify multiple failure to biological therapy in patients with rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2022;14:1759720X221124028.

CAS  PubMed  PubMed Central  Google Scholar 

until Therneau TM. 2009) TL (original S > R port and R maintainer, Elizabeth A, Cynthia C. survival: Survival Analysis [Internet]. 2024 [cited 2025 Mar 30]. Available from: https://cran.r-project.org/web/packages/survival/index.html

Tay JK, Narasimhan B, Hastie T. Elastic net regularization paths for all generalized linear models. J Stat Softw. 2023;106:1–31.

PubMed  PubMed Central  Google Scholar 

Hahsler M, Piekenbrock M, Doran D. Dbscan: fast Density-Based clustering with R. J Stat Softw. 2019;91:1–30.

Google Scholar 

Ogle DH, Doll JC, Wheeler AP. dunnTest()) AD (Provided base functionality of. FSA: Simple Fisheries Stock Assessment Methods [Internet]. 2025 [cited 2025 Mar 30]. Available from: https://cran.r-project.org/web/packages/FSA/index.html

Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S + to analyze and compare ROC curves. BMC Bioinformatics. 2011;12(1):77.

PubMed  PubMed Central  Google Scholar 

Saito T, Rehmsmeier M. Precrec: fast and accurate precision–recall and ROC curve calculations in R. Bioinformatics. 2017;33(1):145–7.

CAS  PubMed  Google Scholar 

Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364(9430):263–9.

PubMed  Google Scholar 

Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.

CAS  PubMed  Google Scholar 

Roodenrijs NMT, Van Der Goes MC, Welsing PMJ, Tekstra J, Lafeber FPJG, Jacobs JWG, et al. Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease. Rheumatology. 2021;60(8):3778–88.

PubMed  Google Scholar 

Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K, et al. Drug retention of 7 biologics and Tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study. Arthritis Res Ther. 2020;22(1):142.

CAS  PubMed  PubMed Central  Google Scholar 

Roodenrijs NMT, Hamar A, Kedves M, Nagy G, Van Laar JM, Van Der Heijde D, et al. Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. RMD Open. 2021;7(1):e001512.

PubMed  PubMed Central  Google Scholar 

Kavanaugh A, Keystone E, Greenberg JD, Reed GW, Griffith JM, Friedman AW, et al. Benefit of biologics initiation in moderate versus severe rheumatoid arthritis: evidence from a united States registry. Rheumatology. 2017;56(7):1095–101.

PubMed  Google Scholar 

Van Nies JAB, Krabben A, Schoones JW, Huizinga TWJ, Kloppenburg M, Van Helm-van Mil D. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis. 2014;73(5):861–70.

PubMed  Google Scholar 

Guo H, Li L, Liu B, Lu P, Cao Z, Ji X, et al. Inappropriate treatment response to dmards: A pathway to difficult-to-treat rheumatoid arthritis. Int Immunopharmacol. 2023;122:110655.

CAS  PubMed  Google Scholar 

PAMUKCU M, İZCİ DURAN T, ULUSOY H, ALTINBAŞ K. Investigation of the correlation between mood disorder symptoms and disease activity and functional status in rheumatoid arthritis patients. Turk J Med Sci 51(6):3008–16.

Matcham F, Norton S, Scott DL, Steer S, Hotopf M. Symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: secondary analysis of a randomized controlled trial. Rheumatology. 2016;55(2):268–78.

PubMed  Google Scholar 

Goldsmith D, Rapaport M, Miller B. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016;21(12):1696–709.

CAS  PubMed  PubMed Central  Google Scholar 

Brock J, Basu N, Schlachetzki JCM, Schett G, McInnes IB, Cavanagh J. Immune mechanisms of depression in rheumatoid arthritis. Nat Rev Rheumatol. 2023;19(12):790–804.

PubMed  Google Scholar 

Roodenrijs NMT, Welsing PMJ, van Roon J, Schoneveld JLM, van der Goes MC, Nagy G, et al. Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search. Rheumatol Oxf Engl. 2022;61(9):3552–66.

CAS  Google Scholar 

Alp G, Cinakli H, Aysin İK, Solmaz D, Akar S. Challenges and insights in managing difficult-to-treat rheumatoid arthritis: real-world clinical perspectives. Clin Exp Rheumatol. 2024.

Leon L, Madrid-Garcia A, Lopez-Viejo P, González-Álvaro I, Novella-Navarro M, Freites Nuñez D, et al. Difficult-to-treat rheumatoid arthritis (D2T RA): clinical issues at early stages of disease. RMD Open. 2023;9(1):e002842.

PubMed  PubMed Central  Google Scholar 

Conran C, Kolfenbach J, Kuhn K, Striebich C, Moreland L. A review of Difficult-to-Treat rheumatoid arthritis: definition, clinical presentation, and management. Curr Rheumatol Rep. 2023;25(12):285–94.

PubMed  Google Scholar 

Bertsias A, Flouri ID, Repa A, Avgoustidis N, Kalogiannaki E, Pitsigavdaki S, et al. Patterns of comorbidities differentially affect long-term functional evolution and disease activity in patients with ‘difficult to treat’ rheumatoid arthritis. RMD Open. 2024;10(1):e003808.

PubMed  PubMed Central  Google Scholar 

Pope JE, Choy EH. C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. Semin Arthritis Rheum. 2021;51(1):219–29.

CAS  PubMed  Google Scholar 

Abdelhafiz D, Baker T, Glascow D, Abdelhafiz A. Biomarkers for the diagnosis and treatment of rheumatoid arthritis – a systematic review. Postgrad Med. 2023;135(3):214–23.

CAS  PubMed  Google Scholar 

Novella-Navarro M, Plasencia C, Tornero C, Navarro-Compán V, Cabrera-Alarcón JL, Peiteado-López D, et al. Clinical predictors of multiple failure to biological therapy in patients with rheumatoid arthritis. Arthritis Res Ther. 2020;22(1):284.

CAS  PubMed  PubMed Central  Google Scholar 

Ruban TN, Jacob B, Pope JE, Keystone EC, Bombardier C, Kuriya B. The influence of age at disease onset on disease activity and disability: results from the Ontario best practices research initiative. Clin Rheumatol. 2016;35(3):759–63.

CAS  PubMed  Google Scholar 

Novella-Navarro M, Balsa A. Difficult-to-Treat rheumatoid arthritis in older adults: implications of ageing for managing patients. Drugs Aging. 2022;39(11):841–9.

PubMed  PubMed Central  Google Scholar